High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary by Matulonis, Ursula A. et al.
High Throughput Interrogation of Somatic Mutations in
High Grade Serous Cancer of the Ovary
Ursula A. Matulonis
1*, Michelle Hirsch
2, Emanuele Palescandolo
1, Eejung Kim
1, Joyce Liu
1, Paul van
Hummelen
1, Laura MacConaill
1, Ronny Drapkin
1,2, William C. Hahn
1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 2Department of Pathology, Women’s and Perinatal
Pathology Division, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
Abstract
Background: Epithelial ovarian cancer is the most lethal of all gynecologic malignancies, and high grade serous ovarian
cancer (HGSC) is the most common subtype of ovarian cancer. The objective of this study was to determine the frequency
and types of point somatic mutations in HGSC using a mutation detection protocol called OncoMap that employs mass
spectrometric-based genotyping technology.
Methodology/Principal Findings: The Center for Cancer Genome Discovery (CCGD) Program at the Dana-Farber Cancer
Institute (DFCI) has adapted a high-throughput genotyping platform to determine the mutation status of a large panel of
known cancer genes. The mutation detection protocol, termed OncoMap has been expanded to detect more than 1000
mutations in 112 oncogenes in formalin-fixed paraffin-embedded (FFPE) tissue samples. We performed OncoMap on a set of
203 FFPE advanced staged HGSC specimens. We isolated genomic DNA from these samples, and after a battery of quality
assurance tests, ran each of these samples on the OncoMap v3 platform. 56% (113/203) tumor samples harbored candidate
mutations. Sixty-five samples had single mutations (32%) while the remaining samples had $2 mutations (24%). 196
candidate mutation calls were made in 50 genes. The most common somatic oncogene mutations were found in EGFR,
KRAS, PDGRFa, KIT, and PIK3CA. Other mutations found in additional genes were found at lower frequencies (,3%).
Conclusions/Significance: Sequenom analysis using OncoMap on DNA extracted from FFPE ovarian cancer samples is
feasible and leads to the detection of potentially druggable mutations. Screening HGSC for somatic mutations in oncogenes
may lead to additional therapies for this patient population.
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Introduction
Epithelial ovarian cancer is the most lethal of all of the
gynecologic malignancies, and new treatments are needed for both
newly diagnosed patients as well as patients with recurrent cancer
[1]. Within epithelial ovarian cancer, HGSC is the most common
subtype and is associated with initial chemotherapy responsiveness
when first diagnosed. However, most cancers recur and become
increasingly chemotherapy resistant. The success of conventional
chemotherapy for the treatment of ovarian cancer has reached a
plateau, and new means of molecularly and genetically charac-
terizing ovarian cancer in order to ‘‘personalize’’ and improve
treatment are needed [2,3].
Activating point mutations in proto-oncogenes have been
observed in many human cancers, and such mutations can confer
‘oncogene addiction’ upon the relevant cancer cells [4]. This
oncogene dependency provides a basis for targeting activated
oncogenes in treatment as exemplified by the success of imatinib
and erlotinib in cancers that harbor BCL-ABL and EGFR
alterations, respectively. Abundant evidence now indicates that
these gain-of-function mutations do not occur randomly within
oncogenes, but instead, mutations affecting a relatively small
number of codons account for the overwhelming majority of
activating events in cancer. For example, single base changes at
codons 12, 13 and 61 in KRAS mutations comprise the majority of
activating oncogenic mutations [5]. Similarly, BRAF mutations
affecting codon 600 constitute .90% of melanoma BRAF
mutations; genetic changes in an additional 10–12 codons account
for most of the remaining cancer-associated BRAF mutations
identified to date [6,7].
To identify these oncogenic mutations in archival tissues, we
have adapted a high-throughput genotyping platform to determine
the mutation status of a large panel of known cancer oncogenes
[8,9]. Specifically, we have developed a mutation detection
protocol, termed OncoMap, which employs mass spectrometric-
based genotyping technology (Sequenom) to identify oncogenic
mutations. The current version of this protocol is able to detect
more than 1000 mutations in 112 commonly mutated genes in
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24433both fresh frozen and paraffin-embedded tissue samples. This
report describes our successful application of OncoMap to a
cohort of patients with advanced HGSC in order to identify
oncogenic mutations.
Results
In the initial OncoMap analysis, 56% (113/203) tumor samples
harbored candidate oncogenic mutations. Sixty-five samples had
single mutations (32%) while the remainder had $2 mutations
(24%). In total, 196 candidate mutation calls were made in 50
genes.
The most commonly mutated oncogenes were EGFR (9.4%),
KRAS (4.5%), PDGFRa (4.5%), KIT (3.0%), and PIK3CA (3%);
others that were less commonly mutated included: BRAF (1%),
CUBN (0.5%), and NRAS (2.5%). We also identified mutations in
many other genes at lower frequencies including: ABL1 (2.5%),
STK11 (2.5%), EPHA1 (2%), RET (1.5%), SMARCB1 (1.5%), ATM
(1%), FLT3 (1%), MLL3 (1%), MYC (1%), NF2 (1%), NOTCH1
(1%), NTRK1 (1%), PIK3R1 (1%), ROBO2 (1%), APC (0.5%), FES
(0.5%), FYN (0.5%), GATA1 (0.5%), NF1 (0.5%), NTRK3 (0.5%),
PALB2 (0.5%), PKHD1 (0.5%), PTEN (0.5%), RUNX1 (0.5%), SMO
(0.5%), SPTAN1 (0.5%), and TSHR (0.5%).
The most common somatic mutation identified involved the
tumor suppressor gene TP53, which was detected in 24.8% of the
samples. Since OncoMap interrogates only a subset of TP53
mutations and does not detect deletion events, the observed
frequency of TP53 alterations agrees with recent work from The
Cancer Genome Atlas Project (TCGA) [10] that has confirmed the
findingthatTP53mutationsarethemostcommonsomaticmutation
in HGSC cancers. In addition, we identified mutations in other
tumor suppressor genes including RB1 (3%) and VHL (3.5%).
Somatic mutations were then validated by hME, and the
following ones were validated: EGFR, HRAS, KRAS, NRAS,
PIK3CA, BRAF, RB1, TP53, ATM, CUBN, and FLNB. Table S1
lists the validated mutations found in our cohort of HGSC.
Discussion
Our group has demonstrated that somatic oncogene mutations
can be detected in HGSC using a Sequenom based assay called
OncoMap that uses DNA derived from FFPE tissue. Although
HGSC is characterized by gene copy number changes [11], low
frequency mutations in a number of oncogenic genes were found
in 56% of the cancers in our 203 sample cohort, and many of these
mutations are potentially druggable using novel biologic agents.
Most mutations were found in low frequency, and most specific
mutations were found in fewer than 5% of samples. Validation
using hME was performed on genes of interest, and several
important genes were found to be mutated; all mutations were not
validated because of cost and level of interest. In clinical practice,
we anticipate that all mutations identified by OncoMap profiling
will be validated in CLIA-approved laboratories.
Thus, OncoMap which uses Sequenom technology is able to
inexpensively screen for multiple mutations using DNA extracted
from FFPE samples in cancers such as HGSC that have multiple
mutations present in low frequency. Other advantages of
OncoMap include the ability to rapidly expand the ‘‘hotspot’’
mutation library as additional mutations are discovered and new
novel biologic agents are successfully tested. Limitations of
OncoMap include that only ‘‘hotspot’’ mutations are located
and that validation of mutations is necessary; other mutations not
included in the OncoMap panel will be missed. Although whole
exome or whole genome sequencing is now possible in research
laboratories, the routine use of these technologies in paraffin
embedded samples is not possible. Thus, OncoMap provides a
rapid, reasonable cost method to identify oncogenic mutations in
human cancer specimens.
The clinical implications of somatic mutations in HGSC are
unknown and will need to be further investigated. Somatic
mutations in cancers can lead to constitutive activation of signaling
pathways that are normally activated by activated growth factor
receptors, and these mutations can lead to overall genomic
instability [12]. Alterations in gene copy number and gene
expression have both been demonstrated to be important in ovarian
cancer, while mutations have been felt to be less important [11].
Several mutated oncogenes of interest were found in our cohort
of HGSC samples tested and analyzed with OncoMap. EGFR was
found to harbor mutations in close to 10% of cases, and EGFR
inhibitors such as erlotinib could be tested in this subset of cancers.
In lung cancer, these inhibitors are used to treat cancers that
harbor exon 20 variants, codon 719 variants, and L858R
substitutions in addition to other types of EGFR mutations
[13,14]. We identified HGSC with a codon 719 variant which
were validated by hME. Thus, testing of EGFR inhibitors appears
warranted when EGFR mutations are detected. EGFR inhibitors
have been tested in ovarian cancer with response rates of 10% or
less [15–17]; however, none of these studies prospectively tested
ovarian cancers for EGFR mutations, a practice now routinely
done for non-small cell lung cancer that has resulted in the
molecularly targeted use of EGFR inhibitors. EGFR mutations and
expression was tested for retrospectively in Schilder et al, and a
partial response was observed in 1 patient who did have an EGFR
mutation [17].
Our rate of PIK3CA mutations of 3% found in HGSC parallels
that found by the Sanger Center [18]. Other groups have reported
low rates of both AKT and PIK3CA mutations but higher frequency
of gene amplification for PIK3CA [19]. Inhibitors of the PI3kinase
pathway are currently being studied in ovarian cancer, and activity
of these agents has been reported in ovarian cancer [20,21]. For
example, MK2206, an AKT inhibitor, was tested in a Phase 1 study
inpatients with advancedsolid tumors. All3 ovariancancerpatients
who were enrolled in this study demonstrated a decrease in their
CA125 levels,suggesting anti-tumor activity of MK-2206 inovarian
cancer. GDC0941, a PI3kinase inhibitor, has also demonstrated
activity in ovarian cancer specifically in situations of PIK3CA
amplification. With the development of additional inhibitors of the
PI3kinase pathway and because of anti-cancer activity of these
agents in ovarian cancer, identification of aberrations of this
pathway will become increasingly important in HGSC.
Other validated genes of interest found in our study include
BRAF, KRAS, HRAS, and NRAS, and all of these genes have
available biologic agents that could target the effects of these
oncogenic mutations. TP53 mutations are found commonly in
ovarian cancer [22], and our data supports and parallels this data.
This work corroborates the recently published TCGA data [10];
future studies will be necessary to correlate the presence of these
mutations with biologic activity and prognosis of the cancer and
whether these mutations predict anti-cancer activity of targeted
biologic agents. In addition, correlating somatic mutations with
other objective assessments of the genetic make up of cancers such
as gene expression profiling and gene copy number will be vital to
understanding a more complete genetic picture of HGSC.
Materials and Methods
Patients and patients’ samples
Pathology records were reviewed between 1999 and 2004 from
the Division of Gynecologic Pathology at the Brigham and
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Gynecology and Obstetrics (FIGO) stage III or IV HGSC ovarian
cancer cases were selected. The Dana-Farber/Harvard Cancer
Center Institutional Review Board (IRB) granted approval to
collect FFPE samples. Because all of the samples were de-
identified, the IRB granted us a waiver to collect the samples
without patient consent.
FFPE samples were reviewed by a gynecologic oncology
pathologist (MH) who reviewed pathology reports as well as FFPE
tissue blocks and selected the areas of highest percentage of cancer
that were eventually cored for DNA extraction. Patients with
known BRCA germline mutations were excluded in this set and
are being studied in another data set. A total of 203 samples were
selected.
DNA extraction and quantification
Genomic DNA was extracted from the cored FFPE patient
tissue samples with QIAamp DNA FFPE Tissue Kit (Qiagen)
according to the manufacturer’s protocol. Briefly, cores were
deparaffinized in xylene and further lysed in denaturing lysis buffer
containing proteinase K. The tissue lysate was incubated at 90uC
to reverse formalin crosslinking. Using QiaCube, the lysate was
Table 1. Known oncogenic mutations tested for in OncoMap.
Gene Name Number of Mutations Gene Name Number of Mutations Gene Name Number of Mutations
ABL1 7 FES 3 PALB2 3
ALB2 1 FGFR2 1 PDGFRA 11
ADAMTSL3 4 FGFR3 6 PDGFRB 3
ALK 7 FGFR4 3 PDPK1 2
AML1/RUNX1 8 FLNB 5 PIK3CA 25
APC 1 FLT3 12 PKHD1 5
AR 2 FMS 3 PTCH 6
ATM 3 FYN 3 PTEN 10
ATP8B1 3 GATA1 16 PTPN11 14
AURKA 3 GNAS 3 RAF1 2
AURKB 1 GUCY1A2 3 RB1 2
AURKC 3 HRAS 1 RET 2
AXL 1 IGF1R 5 RET 12
BMX 1 JAK2 3 ROBO1 2
BRAF 7 JAK3 1 ROBO2 4
BRCA1 3 KIT 13 ROS1 4
BRCA2 6 KRAS 5 SIX4 4
BUB1 2 LRP1B 12 SMAD2 3
C14orf 155 3 LYN 1 SMAD4 4
CDH1 5 MADH4 7 SMARCB1 9
CDKN2A 6 MAP2K4 13 SMO 3
CEBPA 13 MEN1 6 SPTAN1 4
CREBBP 2 MET 5 STK11 7
CTNNB1 16 MLL3 5 SUFU 3
CUBN 3 MPL 3 TBX22 3
DBN1 2 MSH2 2 TCF1 2
DDR1 2 MSH6 3 TEC 1
DDR2 1 MYC 15 TFDP1 2
EGFR 62 MYH1 3 TIAM1 4
EPHA1 2 NF1 5 TIF1 3
EPHA3 18 NF2 11 TP53 11
EPHA4 4 NOTCH1 10 TRIM33 4
EPHA5 6 NPM1 6 TSC1 2
EPHA8 1 NRAS 7 TSHR 5
EPHB1 10 NTRK1 1 VHL 8
EPHB6 5 NTRK1 1 WT1 2
ERBB2 2 NTRK2 1
FBXW7 8 NTRK3 6
doi:10.1371/journal.pone.0024433.t001
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serially, and then eluted in 30 ul of distilled water. Genomic DNA
was quantified using Quant-iT PicoGreen dsDNA Assay Kit
(Invitrogen) per manufacturer’s protocol. 250 ng of genomic DNA
was used for the analysis.
OncoMap v3.0 was performed on all samples, and the genes
and number of mutations tested for in this version of OncoMap
version are listed in Table 1. Initially, primers were designed that
enable mutation detection. Tumor-derived genomic DNA was
subjected to whole genome amplification. Next, multiplexed PCR
was performed on tumor genomic DNA to amplify regions
harboring loci of interest, or ‘query’ nucleotides. After denatur-
ation, PCR products were incubated with oligonucleotides that
anneal immediately adjacent to the query nucleotide, and a primer
extension reaction was performed in the presence of chain-
terminating di-deoxynucleotides that generate allele-specific DNA
products. Primer extension products were spotted onto a specially
designed chip and analyzed by MALDI-TOF mass spectrometry
to determine the mutation status. Since allele (or mutation) calling
depends exclusively on the mass of the resulting primer extension
product, the Sequenom assay does not require expensive
fluorescence primer labeling and has a very low error rate. The
cost of solely running the OncoMap mutational assay is
approximately $200 per sample independent of the number of
samples run.
Once mutations were identified, validation was performed on a
selected subset of mutations using the multi-base hME extension
chemistry as described previously [8,9]. Primers and probes were
designed using Sequenom MassARRAY Assay Design 3.0
software, applying default multi-base extension parameters but
with the following modifications: maximum multiplex level input
adjusted to 6; maximum pass iteration base adjusted to 200.
Supporting Information
Table S1 Validated Mutations by hME. This table lists the
validated mutations found in our cohort of HGSC. Validation was
performed by hME.
(DOC)
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